COMP <GO>
HBIO vs LLY // GROSS PROFIT MARGIN
Harvard Bioscience Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: HBIO 2
— LLY 9
▲ GROSS PROFIT MARGIN LEADER: LLY
LAST: $8.80 (+4.51%) • MKT CAP: $40.1M
gross-margins
57.70%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HBIO VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HBIO | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 57.70% | 83.64% | -25.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 13.66% | 2.30% | +11.36 | HBIO | /fcf-yield <GO> |
| Operating Margin | -56.10% | 40.21% | -96.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -8.10% | 45.51% | -53.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 9.29 | -9.09 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.8 | 66.6 | +2.18 | HBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.1M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HBIO REV | LLY REV | HBIO GROSS % | LLY GROSS % | HBIO FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $86.5M | $65.18B | 57.7% | 83.0% | $5.5M | $16.81B |
| FY 2024 | $94.1M | $45.04B | 58.2% | 81.3% | -$1.2M | $8.82B |
| FY 2023 | $112.3M | $34.12B | — | 79.3% | $14.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HBIO // BETA —
LLY // BETA 0.51